Welcome to Inorbit Therapeutics AB
| About InorbitTX
Inorbit Therapeutics AB (InorbitTX) was founded in 2015. It is a privately owned virtual Drug Discovery and Development company based in the BioVentureHub in Mölndal, near Gothenburg, Sweden. We focus our small molecule drug discovery and development expertise on areas with a high unmet medical need and an excellent…. |
Drug discovery
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis and eventually liver cancer or liver failure. Global rates…. |
Investors
To optimize return on investment, Inorbit aims to develop candidate drugs up to Phase IIb stage, before offering them for out-licensing for further development and marketing. Inorbit will also pursue alliances at earlier stages, i.e. candidate drug selection stage. This will generate revenues to…. |
inorbittx.com 